Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Cancer

• Publication date

  2004-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.EJCA.2003.11.025PMID 15010069
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

  2003cited by this paper
• Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors

  2003cited by this paper
• Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.

  2003cited by this paper
• Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region

  2003cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.

  2002cited by this paper
• Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

  2002cited by this paper
• Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.

  2002cited by this paper
• Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.

  2002cited by this paper
• c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather Than in the Epithelioid Cell Variant

  2002cited by this paper
• STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

  2001cited by this paper
• Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

  2001cited by this paper
• KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

  2001cited by this paper
• Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases.

  2000cited by this paper
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper
• European Journal of Cancer

  1966cited by this paper

• Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GIST

  2025cites this paper
• Spinal Metastases from Gastrointestinal Stromal Tumor: A Case Report

  2025cites this paper
• 18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors

  2025cites this paper
• Long-Term Survival Following Multimodal Therapy with Sunitinib and Surgery for Recurrent Duodenal Gastrointestinal Stromal Tumor

  2025cites this paper
• Molecular Mechanisms and Clinical Implications of Fibroblast Growth Factor Receptor 2 Signaling in Gastrointestinal Stromal Tumors

  2025cites this paper
• Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance

  2025cites this paper
• Therapeutic advances of targeting receptor tyrosine kinases in cancer

  2024cites this paper
• Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling

  2024cites this paper
• English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology

  2024cites this paper
• Cell-permeable PI3 kinase competitive peptide inhibits KIT mutant mediated tumorigenesis of gastrointestinal stromal tumor (GIST)

  2024cites this paper
• Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.

  2024cites this paper
• TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors

  2023cites this paper
• 2023 GEIS Guidelines for gastrointestinal stromal tumors

  2023cites this paper
• The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry

  2023cites this paper
• Medical Oncological Treatment for Patients with Gastrointestinal Stromal Tumour (GIST) - a Systematic Review.

  2022cites this paper
• Adjuvant and Neoadjuvant Therapy for Primary Gastrointestinal Stromal Tumors

  2022cites this paper
• Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review

  2022influential citation
• A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.

  2022cites this paper
• The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours

  2022cites this paper
• miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs

  2022cites this paper
• Impact of neoadjuvant treatment on rectal gastrointestinal stromal tumors

  2022cites this paper
• NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.

  2022cites this paper
• Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor

  2022cites this paper
• Clinical outcomes of surgical and imatinib treatment for rectal gastrointestinal stromal tumours: retrospective cohort study

  2022cites this paper
• Correlation of treatment outcome in sanger/RT-qPCR KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumors with next-generation sequencing results: A single-center report

  2022cites this paper
• Prognostic and predictive values of KIT11-mutated grading system in patients with gastrointestinal stromal tumours A Retrospective Study.

  2021cites this paper
• The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)

  2021cites this paper
• Hypocalcemia with imatinib treatment in chronic myeloid leukemia patients

  2021cites this paper
• Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG

  2021cites this paper
• Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours

  2021cites this paper
• Unresectable GIST liver metastases and liver transplantation: A review and theoretical basis for a new indication.

  2021cites this paper
• KIT Expression Is Regulated by DNA Methylation in Uveal Melanoma Tumors

  2021cites this paper
• Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.

  2021cites this paper
• Imatinib-associated skin rash is related to treatment outcome in patients with unresectable and/or metastatic gastrointestinal stromal tumor.

  2021cites this paper
• Demographic and clinicopathological profile of patients of gastrointestinal stromal tumor from a tertiary care center of North India: An observational study

  2020cites this paper
• Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries.

  2020cites this paper
• Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR

  2020cites this paper
• Approach to Endoscopic Ultrasound-Guided FNA of the Gastrointestinal Tract and Pancreas

  2020cites this paper
• Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors

  2020cites this paper
• Analysis of reliability of different risk classifications for assessment of relapses of gastrointestinal stromal tumors (GIST) — the impact of primary tumor genotyping

  2020cites this paper
• Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.

  2020cites this paper
• New insights into the clinical management of advanced gastrointestinal stromal tumors

  2020cites this paper
• Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation

  2020cites this paper
• Thermal ablation versus hepatic resection for the treatment of liver metastases from gastrointestinal stromal tumors: a retrospective study

  2020influential citation
• Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib

  2020cites this paper
• Clinical significance of the molecular heterogeneity of gastrointestinal stromal tumors and related research: A systematic review.

  2020cites this paper
• Extra-gastrointestinal stromal tumor arising in the lesser omentum with a platelet-derived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review

  2020cites this paper
• Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  2019cites this paper
• Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers

  2019cites this paper
• A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor

  2019cites this paper
• Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib

  2019cites this paper
• Pathologie der Dünndarmtumoren

  2019cites this paper
• Personalized Medicine in Gastrointestinal Stromal Tumors

  2019cites this paper
• TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours

  2019cites this paper
• Mutational testing in gastrointestinal stromal tumor.

  2019cites this paper
• Association between CT imaging features and KIT mutations in small intestinal gastrointestinal stromal tumors

  2019cites this paper
• Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib

  2019cites this paper
• Gastrointestinal stromal tumors

  2019cites this paper
• Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors

  2018cites this paper
• Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors

  2018cites this paper
• CT texture analysis can be a potential tool to differentiate gastrointestinal stromal tumors without KIT exon 11 mutation.

  2018cites this paper
• Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor

  2018cites this paper
• An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor

  2018cites this paper
• Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

  2018cites this paper
• Underuse of exon mutational analysis for gastrointestinal stromal tumors.

  2018cites this paper
• Genomic Applications in Soft Tissue Sarcomas

  2018cites this paper
• The 100 Most Influential Papers and Recent Trends in the Field of Gastrointestinal Stromal Tumours: A Bibliometric Analysis

  2018cites this paper
• Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations

  2018cites this paper
• Evaluation for therapeutic measures to small gastric stromal tumor: A retrospective study of 90 cases.

  2018cites this paper
• Anti-Cancer Drug Sensitivity Assay with Quantitative Heterogeneity Testing Using Single-Cell Raman Spectroscopy

  2018cites this paper
• Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors

  2018cites this paper
• Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors

  2018cites this paper
• Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene

  2018cites this paper
• Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Prognostic significance of KIT exon 11 deletion mutation in intermediate‐risk gastrointestinal stromal tumor

  2017cites this paper
• Is it Feasible to Concomitantly Resect Gastric Gastrointestinal Stromal Tumor during Bariatric Laparoscopic Sleeve Gastrectomy

  2017cites this paper
• Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature

  2017cites this paper
• Insights into ligand stimulation effects on gastro-intestinal stromal tumors signalling.

  2017cites this paper
• Orai1 mediates tumor-promoting store-operated Ca2+ entry in human gastrointestinal stromal tumors via c-KIT and the extracellular signal–regulated kinase pathway

  2017cites this paper
• Mast cell sarcoma of the sternum, clonally related to an antecedent germ cell tumor with a novel D579del KIT mutation

  2017cites this paper
• Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study

  2017cites this paper
• Efficacy of regorafenib in gastrointestinal stromal tumors (GISTs) – a case report.

  2017cites this paper
• GEIS guidelines for gastrointestinal sarcomas (GIST).

  2017cites this paper
• La génétique somatique des tumeurs solides, un incontournable à l’ère de la médecine de précision

  2017cites this paper
• Liquid Biopsy in Gastrointestinal Stromal Tumor

  2017cites this paper
• Cancer genomics guide clinical practice in personalized medicine.

  2017cites this paper
• Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis

  2017cites this paper
• Unraveling the spectrum of KIT mutations in gastrointestinal stromal tumors: An Indian Tertiary Cancer Center Experience

  2017cites this paper
• Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib.

  2017cites this paper
• Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?

  2017cites this paper
• miRNA-133b and miRNA-135a induce apoptosis via the JAK2/STAT3 signaling pathway in human renal carcinoma cells.

  2016cites this paper
• Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.

  2016cites this paper
• Outcomes of surgical treatment of advanced gastrointestinal stromal tumors

  2016cites this paper
• Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo

  2016cites this paper
• Gain of TP53 Mutation in Imatinib-treated SDH-Deficient Gastrointestinal Stromal Tumor and Clinical Utilization of Targeted Next-generation Sequencing Panel for Therapeutic Decision Support

  2016cites this paper
• Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?

  2016cites this paper
• Identification of the two KIT isoforms and their expression status in canine hemangiosarcomas

  2016cites this paper
• Combined Therapy of Gastrointestinal Stromal Tumors.

  2016cites this paper
• Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.

  2016cites this paper